Impact of Semaglutide 2.4 mg on Reducing Health Inequality in the US: A Modeling Study
That is the title of a study presented this week at the Obesity Week conference. This is work used a distributional cost effectiveness analysis approach for measuring the value of semaglutide 2.4 mg for the treatment of patients with obesity and overweight. It was conducted with co-authors Joshua Toliver, Mads Faurby, Jaehong Kim, Sanjana Muthukrishnan…